This top fund manager just called these leading ASX shares a buy

WAM thinks that these two ASX shares are buys.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A stopwatch ticking close to the 12 where the words on the face say 'Time to Buy' indicating its the bottom of the falling market and time to buy ASX shares

Image source: Getty Images

Key points

  • Fund manager Wilson Asset Management (WAM) has outlined two ASX shares with potential
  • The first stock is pathology business Australian Clinical Labs which is benefiting from the high level of COVID testing
  • The second company is building and restoration services Johns Lyng which is growing market share and opening up new growth opportunities

Leading fund manager Wilson Asset Management (WAM) has named two ASX shares in its portfolios that it thinks are buys.

Every month, WAM talks about some of the businesses that have performed well and outlines the bullish factors for thinking about the stocks.

Two of the featured ASX shares this month comes from WAM Research Limited (ASX: WAX) and WAM Capital Limited (ASX: WAM), which sometimes target opportunities from the smaller end of the ASX, like these two:

Australian Clinical Labs Ltd (ASX: ACL)

Australian Clinical Labs is described as a leading provider of pathology services in Australia, with 86 accredited laboratories performing services for more than 8 million people annually.

In December, Australian Clinical Labs upgraded its expectations for the FY22 first-half net profit after tax (NPAT) to between $116.3 million to $128 million. This was increased from the previous guidance of between $86.3 million to $94.9 million.

The fund manager notes that the ASX share is experiencing strong demand for coronavirus testing, particularly during the Omicron variant outbreak and recently completed the acquisition of Medlab Pathology, doubling its market share to 20.4% in New South Wales.

WAM thinks that Australian Clinical Labs is a high-quality pathology business that can continue to grow organically through market share gains, due to its "superior technology and processes". The fund manager notes that Australian Clinical Labs has a very strong balance sheet and it also sees the potential for acquisitions in the future that can add to profit.

Johns Lyng Group Ltd (ASX: JLG)

Another ASX share that WAM likes is Johns Lyng which provides building and restoration services across Australia for properties and contents damaged by insurable events, including impact, weather, and fire events.

It operates in all major metropolitan areas and in high-risk regional areas, such as Far North Queensland.

WAM pointed out that in December, the company announced the acceleration of its US growth strategy through the acquisition of Reconstruction Experts, a leading provider of insurance-focused vendor managed repairs services for US$144 million.

This acquisition, considered highly strategic, adds to the company's earnings per share (EPS) and equated to 7.8x earnings before interest, tax, depreciation and amortisation (EBITDA) for the 12 months to 30 June 2021.

The fund manager decided to invest in Johns Lyng Group based on the view that as the largest and most sophisticated provider of emergency building works, the company will continue to grow through market share gains and acquisition.

WAM believes that with the recent acquisition, the company has added another material growth pillar that will underpin longer-term aspirations and earnings growth.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Australian Clinical Labs Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Opinions

Woman thinking in a supermarket.
Opinions

Should I buy Woolworths shares at $37?

Are Woolworths shares worth putting in the shopping basket?

Read more »

Woman looking at her smartphone and analysing share price.
Opinions

Warren Buffett is invested in IAG shares, should you be?

IAG is one of Australia’s biggest insurers. Is it a big opportunity?

Read more »

man looking through binoculars
Opinions

3 ASX All Ordinaries shares I'm watching like a hawk in March

These three ASX shares look very compelling to me.

Read more »

three reasons to buy asx shares represented by man in red jumper holding up three fingers
Bank Shares

3 reasons the 8% NAB dividend yield looks safe to me

The bank could keep paying a very good dividend.

Read more »

Three young people in business attire sit around a desk and discuss.
Opinions

Underappreciated: 3 ASX shares I believe were the quiet achievers of earnings season

Solid results, marginal share price moves... could the market be missing something?

Read more »

Young girl drinking milk showing off muscles.
Opinions

At almost $7, can the A2 Milk share price go any higher?

Is the market still underestimating A2 Milk?

Read more »

A woman peers through a bunch of recycled clothes on hangers and looks amazed.
Opinions

Bargain buys? 3 ASX All Ords shares trading at 52-week lows right now

Are investors being too negative about these ASX shares?

Read more »

A mature age woman with a groovy short haircut and glasses, sits at her computer, pen in hand thinking about information she is seeing on the screen.
Dividend Investing

Is right now the time to buy Wesfarmers shares for passive income?

The owner of Bunnings is still paying dividends. So is it time to put shares in the shopping basket?

Read more »